CO2021002706A2 - Inhibición de la integrina ανβ6 - Google Patents
Inhibición de la integrina ανβ6Info
- Publication number
- CO2021002706A2 CO2021002706A2 CONC2021/0002706A CO2021002706A CO2021002706A2 CO 2021002706 A2 CO2021002706 A2 CO 2021002706A2 CO 2021002706 A CO2021002706 A CO 2021002706A CO 2021002706 A2 CO2021002706 A2 CO 2021002706A2
- Authority
- CO
- Colombia
- Prior art keywords
- ανβ6
- compounds
- assay
- inhibition
- integrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Abstract
Se describen inhibidores de molécula pequeña de la integrina ανβ6, y métodos para usarlos para tratar una serie de enfermedades y afecciones. Los solicitantes han descubierto nuevos compuestos inhibidores de la integrina ανβ6 y han evaluado la posesión, el rendimiento y la utilidad de ejemplos representativos de tales compuestos, tanto para la potencia bioquímica (por ejemplo, mediante el uso del ensayo del Ejemplo 35 para evaluar los ensayos de polarización de fluorescencia de compuestos para la unión de ανβ6) como las propiedades de permeabilidad in vitro (por ejemplo, mediante el uso del ensayo del Ejemplo 36 para evaluar la permeabilidad en MDCK).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862724423P | 2018-08-29 | 2018-08-29 | |
US201962859457P | 2019-06-10 | 2019-06-10 | |
PCT/US2019/048782 WO2020047239A1 (en) | 2018-08-29 | 2019-08-29 | INHIBITING αV β6 INTEGRIN |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021002706A2 true CO2021002706A2 (es) | 2021-05-20 |
Family
ID=67809398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0002706A CO2021002706A2 (es) | 2018-08-29 | 2021-02-26 | Inhibición de la integrina ανβ6 |
Country Status (22)
Country | Link |
---|---|
US (4) | US20200071322A1 (es) |
EP (2) | EP4086254A1 (es) |
JP (1) | JP2021535141A (es) |
KR (1) | KR20210065935A (es) |
CN (1) | CN112805001A (es) |
AU (1) | AU2019327475A1 (es) |
BR (1) | BR112021003859A2 (es) |
CA (1) | CA3109534A1 (es) |
CL (1) | CL2021000484A1 (es) |
CO (1) | CO2021002706A2 (es) |
CR (1) | CR20210109A (es) |
DO (1) | DOP2021000035A (es) |
EC (1) | ECSP21013620A (es) |
IL (1) | IL280782A (es) |
MA (1) | MA51066A (es) |
MX (1) | MX2021002181A (es) |
PE (1) | PE20211640A1 (es) |
PH (1) | PH12021550404A1 (es) |
SG (1) | SG11202101913PA (es) |
TW (1) | TW202035400A (es) |
UY (1) | UY38353A (es) |
WO (1) | WO2020047239A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201823208A (zh) | 2016-09-07 | 2018-07-01 | 美商普萊恩醫療公司 | N-醯基胺基酸化合物及其使用方法 |
US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
US20180244648A1 (en) | 2017-02-28 | 2018-08-30 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
WO2019173653A1 (en) | 2018-03-07 | 2019-09-12 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
EA202190134A1 (ru) | 2018-06-27 | 2021-03-26 | Плайэнт Терапьютикс, Инк. | Соединения аминокислот с неразветвленными линкерами и способы их применения |
CR20210109A (es) | 2018-08-29 | 2021-06-24 | Morphic Therapeutic Inc | INHIBICIÓN DE LA INTEGRINA av ß6 |
TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
CR20210213A (es) | 2018-10-30 | 2021-06-24 | Gilead Sciences Inc | Derivados de quinolina como inhibidores de la integrina alfa4beta7 |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
CN116323633A (zh) * | 2020-09-11 | 2023-06-23 | 箭头药业股份有限公司 | 骨骼肌递送平台及使用方法 |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
JPH07501063A (ja) | 1991-11-14 | 1995-02-02 | グラクソ、グループ、リミテッド | フィブリノーゲン依存性血小板凝集阻害剤としてのピペリジン酢酸誘導体 |
JPH07503459A (ja) | 1992-01-21 | 1995-04-13 | グラクソ、グループ、リミテッド | 酢酸誘導体 |
EP0623615B1 (de) | 1993-05-01 | 1999-06-30 | MERCK PATENT GmbH | Substituierte 1-Phenyl-oxazolidin-2-on Derivate, deren Herstellung und deren Verwendung als Adhäsionsrezeptor-Antagonisten |
US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
US20010034445A1 (en) | 1995-12-29 | 2001-10-25 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
AU1353897A (en) | 1995-12-29 | 1997-07-28 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
WO1997024124A1 (en) | 1995-12-29 | 1997-07-10 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
EP0880511A4 (en) | 1996-01-16 | 1999-06-16 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
EP0796855B1 (de) | 1996-03-20 | 2002-02-06 | Hoechst Aktiengesellschaft | Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
PT891332E (pt) | 1996-03-29 | 2004-07-30 | Pfizer | Derivados de 6-fenilpiridil-2-amina |
JP2002511052A (ja) | 1996-08-29 | 2002-04-09 | メルク エンド カンパニー インコーポレーテッド | インテグリンアンタゴニスト |
EP0946165B1 (en) | 1996-10-30 | 2003-04-09 | Merck & Co., Inc. | Integrin antagonists |
US5952341A (en) | 1996-10-30 | 1999-09-14 | Merck & Co., Inc. | Integrin antagonists |
JP2001524079A (ja) | 1997-04-07 | 2001-11-27 | メルク エンド カンパニー インコーポレーテッド | ガンの治療方法 |
AU7105498A (en) | 1997-04-14 | 1998-11-11 | Merck & Co., Inc. | Combination therapy for the prevention and treatment of osteoporosis |
JP2001524481A (ja) | 1997-11-26 | 2001-12-04 | デュポン ファーマシューティカルズ カンパニー | αVβ3アンタゴニストとしての1,3,4−チアジアゾール類および1,3,4−オキサジアゾール類 |
WO1999030709A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
WO1999030713A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
AU741769B2 (en) | 1997-12-17 | 2001-12-06 | Merck Sharp & Dohme Corp. | Integrin receptor antagonists |
US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
KR20010033248A (ko) | 1997-12-17 | 2001-04-25 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
JP2002521450A (ja) | 1998-07-29 | 2002-07-16 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体アンタゴニスト |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
CA2355874A1 (en) | 1998-12-19 | 2000-06-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | .alpha.v.beta.6 integrin inhibitors |
WO2000046215A1 (en) | 1999-02-03 | 2000-08-10 | Merck & Co., Inc. | Benzazepine derivatives as alpha-v integrin receptor antagonists |
US6723711B2 (en) | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
WO2000072801A2 (en) | 1999-06-02 | 2000-12-07 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
JP2003502373A (ja) | 1999-06-23 | 2003-01-21 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体アンタゴニスト |
DE19933173A1 (de) | 1999-07-15 | 2001-01-18 | Merck Patent Gmbh | Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
GB9929988D0 (en) | 1999-12-17 | 2000-02-09 | Celltech Therapeutics Ltd | Chemical compounds |
CA2397194C (en) | 2000-01-20 | 2011-05-17 | Mark E. Duggan | Alpha v integrin receptor antagonists |
EP1254116A4 (en) | 2000-01-24 | 2003-04-23 | Merck & Co Inc | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS |
JP2004511434A (ja) | 2000-06-15 | 2004-04-15 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
AU2001292598B2 (en) | 2000-09-14 | 2006-06-29 | Merck & Co., Inc. | Alpha V integrin receptor antagonists |
WO2002022616A2 (en) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
US20050004199A1 (en) | 2000-09-18 | 2005-01-06 | George Hartman | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
KR100854424B1 (ko) | 2001-01-29 | 2008-08-27 | 3-디멘져널 파마슈티칼즈 인코오포레이티드 | 치환된 인돌 및 인테그린 길항제로서의 이들의 용도 |
DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
US7109191B2 (en) | 2001-05-03 | 2006-09-19 | Merck & Co., Inc. | Benzazepinone alpha vintegrin receptor antagonists |
US20040043988A1 (en) | 2001-06-15 | 2004-03-04 | Khanna Ish Kurmar | Cycloalkyl alkanoic acids as intergrin receptor antagonists |
DE10204789A1 (de) | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta6 |
RU2333210C2 (ru) | 2002-08-16 | 2008-09-10 | Янссен Фармацевтика Н.В. | Соединения пиперидинила, селективно связывающие интегрины |
FI20041129A0 (fi) | 2004-08-30 | 2004-08-30 | Ctt Cancer Targeting Tech Oy | Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi |
AR059224A1 (es) | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
JP2009539815A (ja) | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のa5b1アンタゴニストとしてのN−(ベンゾイル)−O−[2−(ピリジン−2−イルアミノ)エチル]−L−チロシン誘導体と関連化合物 |
AR067329A1 (es) | 2007-06-13 | 2009-10-07 | Bristol Myers Squibb Co | Analogos dipeptidos como inhibidores del factor de coagulacion |
ES2428896T3 (es) | 2007-11-16 | 2013-11-12 | Ube Industries, Ltd. | Compuesto de benzacepinona |
US20120289481A1 (en) | 2011-05-13 | 2012-11-15 | O'neil Jennifer | Compositions and methods for treating cancer |
JP6215324B2 (ja) | 2012-07-18 | 2017-10-18 | セントルイス ユニバーシティ | インテグリンアンタゴニストとしてのβアミノ酸誘導体 |
US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
EP2784511A1 (en) | 2013-03-27 | 2014-10-01 | Universität Zürich | Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma |
GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
WO2015103643A2 (en) | 2014-01-06 | 2015-07-09 | The General Hospital Corporation | Integrin antagonists |
MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
WO2015179823A2 (en) | 2014-05-23 | 2015-11-26 | The California Institute For Biomedical Research | Lung localized inhibitors of alpha(v)beta 6 |
WO2016022851A1 (en) | 2014-08-06 | 2016-02-11 | Children's Medical Center Corporation | Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof |
GB201417002D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
AU2016219906B2 (en) | 2015-02-19 | 2020-10-01 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
WO2016153054A1 (ja) | 2015-03-25 | 2016-09-29 | 富士フイルム株式会社 | 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体 |
RU2017141561A (ru) | 2015-04-30 | 2019-05-31 | Сайфлуор Лайф Сайенсиз, Инк. | Производные тетрагидронафтиридинилпропионовой кислоты и их применение |
RU2729518C2 (ru) | 2015-12-30 | 2020-08-07 | Сент-Луис Юниверсити | Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина |
GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
GB201604680D0 (en) * | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
GB201604681D0 (en) * | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
WO2018009501A1 (en) | 2016-07-05 | 2018-01-11 | The Rockefeller University | Tetrahydronaphthyridinepentanamide integrin antagonists |
TW201823208A (zh) | 2016-09-07 | 2018-07-01 | 美商普萊恩醫療公司 | N-醯基胺基酸化合物及其使用方法 |
KR102634762B1 (ko) | 2016-11-01 | 2024-02-06 | 애로우헤드 파마슈티컬스 인코포레이티드 | 알파-v 베타-6 인테그린 리간드 및 그의 용도 |
WO2018085552A1 (en) | 2016-11-02 | 2018-05-11 | Saint Louis University | Integrin antagonists |
WO2018085578A1 (en) | 2016-11-02 | 2018-05-11 | Saint Louis University | Integrin inhibitors in combination with an agent which interacts with a chemokine receptor |
EP3538526B1 (en) | 2016-11-08 | 2024-04-10 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors |
LT3538525T (lt) | 2016-11-08 | 2022-09-26 | Bristol-Myers Squibb Company | Propiono rūgštys, pakeistos 3 padėtyje, kaip alfa v integrino inhibitoriai |
AU2017359027A1 (en) | 2016-11-08 | 2019-06-20 | Bristol-Myers Squibb Company | Indazole derivatives as αV integrin antagonists |
US10717736B2 (en) | 2016-11-08 | 2020-07-21 | Bristol-Myers Squibb Company | Pyrrole amides as alpha V integrin inhibitors |
CA3042684A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Azole amides and amines as .alpha.v integrin inhibitors |
US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
RU2019116820A (ru) | 2016-12-29 | 2021-01-29 | Сент-Луис Юниверсити | Антагонисты интегрина |
US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
US20180244648A1 (en) | 2017-02-28 | 2018-08-30 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
WO2019173653A1 (en) | 2018-03-07 | 2019-09-12 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
EA202190134A1 (ru) | 2018-06-27 | 2021-03-26 | Плайэнт Терапьютикс, Инк. | Соединения аминокислот с неразветвленными линкерами и способы их применения |
WO2020009889A1 (en) | 2018-07-03 | 2020-01-09 | Saint Louis University | ALPHAvBETA1 INTEGRIN ANTAGONISTS |
WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
CR20210109A (es) | 2018-08-29 | 2021-06-24 | Morphic Therapeutic Inc | INHIBICIÓN DE LA INTEGRINA av ß6 |
EP3843728A4 (en) | 2018-08-29 | 2022-05-25 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
UY38352A (es) | 2018-08-29 | 2020-03-31 | Morphic Therapeutic Inc | Inhibidores de integrina alfavbeta6 |
TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
CA3136745A1 (en) | 2019-04-08 | 2020-10-15 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
-
2019
- 2019-08-29 CR CR20210109A patent/CR20210109A/es unknown
- 2019-08-29 MA MA051066A patent/MA51066A/fr unknown
- 2019-08-29 PE PE2021000252A patent/PE20211640A1/es unknown
- 2019-08-29 TW TW108131114A patent/TW202035400A/zh unknown
- 2019-08-29 KR KR1020217006113A patent/KR20210065935A/ko unknown
- 2019-08-29 JP JP2021510691A patent/JP2021535141A/ja active Pending
- 2019-08-29 CA CA3109534A patent/CA3109534A1/en active Pending
- 2019-08-29 WO PCT/US2019/048782 patent/WO2020047239A1/en active Application Filing
- 2019-08-29 AU AU2019327475A patent/AU2019327475A1/en active Pending
- 2019-08-29 SG SG11202101913PA patent/SG11202101913PA/en unknown
- 2019-08-29 EP EP22173105.2A patent/EP4086254A1/en active Pending
- 2019-08-29 BR BR112021003859-0A patent/BR112021003859A2/pt unknown
- 2019-08-29 US US16/555,589 patent/US20200071322A1/en not_active Abandoned
- 2019-08-29 UY UY0001038353A patent/UY38353A/es unknown
- 2019-08-29 EP EP19194490.9A patent/EP3617206A1/en not_active Withdrawn
- 2019-08-29 MX MX2021002181A patent/MX2021002181A/es unknown
- 2019-08-29 CN CN201980056588.3A patent/CN112805001A/zh active Pending
-
2020
- 2020-07-27 US US16/939,848 patent/US20200354359A1/en not_active Abandoned
- 2020-08-24 US US17/001,086 patent/US11021480B2/en active Active
-
2021
- 2021-02-10 IL IL280782A patent/IL280782A/en unknown
- 2021-02-25 DO DO2021000035A patent/DOP2021000035A/es unknown
- 2021-02-25 CL CL2021000484A patent/CL2021000484A1/es unknown
- 2021-02-26 CO CONC2021/0002706A patent/CO2021002706A2/es unknown
- 2021-02-26 PH PH12021550404A patent/PH12021550404A1/en unknown
- 2021-02-26 EC ECSENADI202113620A patent/ECSP21013620A/es unknown
- 2021-04-23 US US17/239,045 patent/US11739087B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MA51066A (fr) | 2020-10-14 |
US11739087B2 (en) | 2023-08-29 |
CN112805001A (zh) | 2021-05-14 |
US20200071322A1 (en) | 2020-03-05 |
US11021480B2 (en) | 2021-06-01 |
DOP2021000035A (es) | 2021-06-30 |
CA3109534A1 (en) | 2020-03-05 |
UY38353A (es) | 2020-03-31 |
PE20211640A1 (es) | 2021-08-24 |
MX2021002181A (es) | 2021-07-15 |
EP4086254A1 (en) | 2022-11-09 |
WO2020047239A1 (en) | 2020-03-05 |
SG11202101913PA (en) | 2021-03-30 |
ECSP21013620A (es) | 2021-05-31 |
EP3617206A1 (en) | 2020-03-04 |
BR112021003859A2 (pt) | 2021-05-18 |
CL2021000484A1 (es) | 2021-09-03 |
KR20210065935A (ko) | 2021-06-04 |
AU2019327475A1 (en) | 2021-03-11 |
JP2021535141A (ja) | 2021-12-16 |
PH12021550404A1 (en) | 2021-10-04 |
IL280782A (en) | 2021-04-29 |
US20220073511A1 (en) | 2022-03-10 |
US20200385384A1 (en) | 2020-12-10 |
US20200354359A1 (en) | 2020-11-12 |
CR20210109A (es) | 2021-06-24 |
TW202035400A (zh) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021002706A2 (es) | Inhibición de la integrina ανβ6 | |
WO2020047207A8 (en) | Inhibitors of (alpha-v)(beta-6) integrin | |
CU24387B1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
CL2018000106A1 (es) | Moléculas de anticuerpo que se unen a cd45 | |
BRPI0911105A2 (pt) | compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seu uso | |
ECSP11010889A (es) | INHIBIDORES DE cMET | |
CR20110309A (es) | Compuestos orgánicos | |
CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
CR11492A (es) | Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i | |
ECSP10010129A (es) | Inhibidores de quinasas símil polo | |
CL2011001485A1 (es) | Compuestos heterociclicos nitrogenados sustituidos; inhibidor de proteinas anti-apoptoticas bc1-2; sus composiciones farmaceuticas; y su uso para tratar enfermedades causadas por un exceso de plaquetas, cancer de pulmon de celulas pequeñas, trombocitemia esencial, policitemia vera, restenosis. | |
CR20140058A (es) | Derivados de 5-flúor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2-(1h)ona | |
CL2011000242A1 (es) | Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia. | |
BR112013025777A2 (pt) | imidazopiridazinas como inibidores da quinase akt | |
UY31479A1 (es) | 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiinflamatorios | |
BRPI0519710A2 (pt) | aminoÁlcoois tricÍclicos, processo para sua preparaÇço e seu emprego como anti-inflamatàrio | |
UY34008A (es) | ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. | |
ECSP18074962A (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
CL2012000450A1 (es) | Compuestos derivados de isoxazolidina de glucocorticoides, de la serie de los glucocorticoides; composicion farmaceutica; combinacion farmaceutica; proceso para su preparacion; y uso para disminuir la cantidad, acividad y movimiento de las celulas inflamatorias. | |
AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
BRPI0515186A (pt) | derivados de alquilideno-tetrahidronaftaleno, processo para a sua produção e seu uso como antiinflamatório | |
MX2020004554A (es) | Ligandos de integrina y usos de estos. | |
BRPI0508471A8 (pt) | compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos | |
GT200500382A (es) | Sulfonamido-macrociclos y sus sales como inhibidores de tie2, composicion farmaceutica que comprende estos compuestos, metodo de prepararlos y su uso | |
MX2020009022A (es) | Uso de alcoxipirazoles como inhibidores de la nitrificacion. |